Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neuraxis (NRXS) EBITDA Margin (2022 - 2025)

Neuraxis' EBITDA Margin history spans 4 years, with the latest figure at 258.82% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 1111.0% year-over-year to 258.82%; the TTM value through Sep 2025 reached 225.43%, up 7232.0%, while the annual FY2024 figure was 266.46%, 445.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 258.82% at Neuraxis, down from 192.14% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1194.27% in Q3 2022 and bottomed at 633.0% in Q3 2023.
  • The 4-year median for EBITDA Margin is 247.71% (2024), against an average of 152.39%.
  • The largest annual shift saw EBITDA Margin plummeted -182728bps in 2023 before it skyrocketed 38530bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 160.86% in 2022, then tumbled by -90bps to 305.42% in 2023, then surged by 37bps to 192.68% in 2024, then plummeted by -34bps to 258.82% in 2025.
  • Per Business Quant, the three most recent readings for NRXS's EBITDA Margin are 258.82% (Q3 2025), 192.14% (Q2 2025), and 256.25% (Q1 2025).